Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –

– New analysis increases overall confidence in the Phase 2 trial results –

Read more at globenewswire.com